CD40 Ligand (CD40L) Antibody Global Market Report 2025
상품코드:1815881
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
CD40 리간드(CD40L) 항체 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 10.0%를 나타내 10억 1,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 개별화의 채용 증가, 자가면역요법 및 이식요법에 대한 연구투자 증가, 신규치료에 대한 규제당국의 승인 증가, 장기이식에 있어서의 CD40L 항체의 유용성에 대한 인식 증가, 면역억제 용도의 임상시험의 확대에 기인한다고 생각됩니다. 예측 기간 동안의 주요 동향은 항체 공학의 진보, 표적 치료를 위한 이중특이적 항체의 개발, 전달 방법의 혁신, 병용 요법의 진보, 개인화된 의료의 진보, 더 나은 환자 선택을 위한 바이오마커 개발의 진보 등을 포함합니다.
향후 5년간의 성장률 10.0%라고 하는 예측은 이 시장의 전회 예측으로부터의 0.4%라고 하는 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 네덜란드와 이스라엘에서 공급되는 CD40L 항체 치료제의 비용을 증가시키고, 새로운 치료 개발을 지연시키고, 면역학 연구 개발비를 상승시킬 수 있기 때문에 미국의 자가면역 연구에 큰 과제가 될 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
자가면역 질환의 유병률 증가는 CD40 리간드(CD40L) 항체 시장 성장을 가속할 것으로 예측됩니다. 자가면역질환은 면역체계가 실수로 신체 자신의 세포를 공격함으로써 발생하여 류마티스 관절염, 루푸스, 1형 당뇨병 등의 증상을 유발합니다. 이러한 질병의 이환율 상승은 환경적 유인, 유전적 소인, 라이프 스타일의 변화, 진단 의식의 향상 등의 요인이 관련되어, 이들 모두가 발견률의 향상에 기여하고 있습니다. CD40L 항체는 면역계의 과도한 반응을 조절함으로써 자가면역 질환을 관리하는 유망한 치료 접근법으로 부상하고 있습니다. 예를 들어, 2024년 7월 호주 정부 기관인 호주 보건 복지 연구소(Australian Institute of Health and Welfare)는 2022년에는 약 51만 4,000명의 호주인(인구의 2.0%)이 관절 류마티스를 앓았다고 보고했습니다. 이 질환은 여성의 2.5%, 남성의 1.6%가 영향을 받습니다. 그 결과, 자가면역질환의 이환율 증가가 CD40 리간드(CD40L) 항체 시장 확대에 박차를 가하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 CD40 리간드(CD40L) 항체 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 CD40 리간드(CD40L) 항체 시장 : 성장률 분석
세계의 CD40 리간드(CD40L) 항체 시장 실적 : 규모와 성장(2019-2024년)
세계의 CD40 리간드(CD40L) 항체 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 CD40 리간드(CD40L) 항체 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 CD40 리간드(CD40L) 항체 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일클론 항체
다클론 항체
세계의 CD40 리간드(CD40L) 항체 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
유세포 분석법
효소결합 면역흡착 분석법(ELISA)
웨스턴 블롯
면역침전법
면역형광법
기타 용도
세계의 CD40 리간드(CD40L) 항체 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
연구기관
전문 클리닉
기타 최종 사용자
세계의 CD40 리간드(CD40L) 항체 시장 : 단일클론 항체 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
완전 인간 단일클론 항체
인간화 단일클론 항체
키메라 단일클론 항체
세계의 CD40 리간드(CD40L) 항체 시장 : 다클론 항체 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
토끼 다클론 항체
염소 다클론 항체
마우스 다클론 항체
제7장 지역별/국가별 분석
세계의 CD40 리간드(CD40L) 항체 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 CD40 리간드(CD40L) 항체 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
CD40 리간드(CD40L) 항체 시장 : 경쟁 구도
CD40 리간드(CD40L) 항체 시장 : 기업 프로파일
Thermo Fisher Scientific Co. Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Amgen Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bio-Rad Laboratories Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bio-Techne Corporation : 개요, 제품 및 서비스, 전략 및 재무 분석
Kiniksa Pharmaceuticals Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
BioLegend
Cytek Biosciences Inc.
Sino Biological Inc.
ACROBiosystems
Elabscience Biotechnology Inc.
Cayman Chemical
Eledon Pharmaceuticals
Cell Signaling Technology
Enzo Biochem
GeneTex
GeminiBio
Creative Biolabs
BPS Bioscience Inc.
LSBio
MyBiosource Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
CD40 리간드(CD40L) 항체 시장(2029년) : 새로운 기회를 제공하는 국가
CD40 리간드(CD40L) 항체 시장(2029년) : 새로운 기회를 제공하는 부문
CD40 리간드(CD40L) 항체 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
CD40 ligand (CD40L) antibody is a therapeutic agent that targets the CD40L protein to inhibit CD40-CD40L interactions, thereby modulating immune responses for use in autoimmune diseases, transplant rejection, and cancer immunotherapy. By blocking this interaction, CD40L antibodies play a crucial role in regulating immune activation.
The primary types of CD40L antibodies include monoclonal and polyclonal antibodies. Monoclonal antibodies are derived from a single cell clone and are specifically designed to target a particular epitope on an antigen. These antibodies are used in various applications, including flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blotting, immunoprecipitation, and immunofluorescence. The key end users of CD40L antibodies include hospitals, research institutes, specialty clinics, and other medical and scientific institutions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The cd40 ligand (cd40l) antibody market research report is one of a series of new reports from The Business Research Company that provides cd40 ligand (cd40l) antibody market statistics, including the cd40 ligand (cd40l) antibody industry's global market size, regional shares, competitors with a cd40 ligand (cd40l) antibody market share, detailed cd40 ligand (cd40l) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the cd40 ligand (cd40l) antibody industry. This cd40 ligand (cd40l) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The CD40 ligand (CD40L) antibody market size has grown strongly in recent years. It will grow from $0.63 billion in 2024 to $0.69 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increase in prevalence of autoimmune diseases, growth in demand for targeted cancer treatments, expanding research on immune modulation, regulatory approvals for novel biologics, rise in healthcare expenditures, and rise in adoption of personalized medicine approaches.
The CD40 ligand (CD40L) antibody market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to rising adoption of personalized medicine, growing research investments in autoimmune and transplant therapies, rising regulatory approvals for novel treatments, heightened awareness of CD40L antibody benefits in organ transplantation, and expanding clinical trials for immunosuppressive applications. Major trends in the forecast period include advancements in antibody engineering, development of bispecific antibodies for targeted therapies, innovations in delivery methods, advancements in combination therapies, advancements in personalized medicine, and advancements in developing biomarkers for better patient selection.
The forecast of 10.0% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. autoimmune research by increasing costs of CD40L antibody therapies sourced from the Netherlands and Israel, potentially delaying novel treatment development and raising immunology research and development expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of autoimmune disorders is expected to drive growth in the CD40 ligand (CD40L) antibody market. Autoimmune disorders arise when the immune system mistakenly attacks the body's own cells, leading to conditions such as rheumatoid arthritis, lupus, and type 1 diabetes. The rising incidence of these disorders can be linked to factors including environmental triggers, genetic predisposition, lifestyle changes, and greater diagnostic awareness, all of which contribute to higher detection rates. CD40L antibodies are emerging as a promising therapeutic approach for managing autoimmune disorders by regulating the immune system's overactive response. For example, in July 2024, the Australian Institute of Health and Welfare, an Australian government agency responsible for health and welfare statistics, reported that in 2022, approximately 514,000 Australians (2.0% of the population) were living with rheumatoid arthritis. The condition affected 2.5% of females and 1.6% of males. As a result, the rising incidence of autoimmune disorders is fueling the expansion of the CD40L antibody market.
Companies in the CD40L antibody market are advancing clinical trials and expanding therapeutic applications to enhance immune modulation. Clinical trials systematically assess the safety, efficacy, and optimal use of medical treatments. For example, in September 2023, Eledon Pharmaceuticals Inc., a US-based biotechnology company, announced the use of its anti-CD40L antibody, Tegoprubart, in a clinical trial following the second-ever genetically modified pig heart transplant. The trial aimed to evaluate its role in preventing organ rejection and expanding therapeutic applications in organ transplantation. Additionally, Tegoprubart has demonstrated potential in treating autoimmune diseases by modulating immune responses.
In January 2023, eGenesis Inc., a US-based biotechnology company, partnered with Eledon Pharmaceuticals Inc. Through this collaboration, eGenesis aims to integrate Eledon's anti-CD40L antibody, Tegoprubart, into its preclinical research focused on developing human-compatible organs and cells for transplantation. Eledon Pharmaceuticals Inc. specializes in the development of novel immunotherapies, and this strategic partnership is expected to contribute to advancements in transplantation research and immunotherapy development.
Major players in the cd40 ligand (cd40l) antibody market are Thermo Fisher Scientific Co. Ltd., Amgen Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Kiniksa Pharmaceuticals Ltd., BioLegend, Cytek Biosciences Inc., Sino Biological Inc., ACROBiosystems, Elabscience Biotechnology Inc., Cayman Chemical, Eledon Pharmaceuticals, Cell Signaling Technology, Enzo Biochem, GeneTex, GeminiBio, Creative Biolabs, BPS Bioscience Inc., LSBio, MyBiosource Inc., Boster Biological Technology, Bio X Cell, Assay Genie, Abeomics, Leinco Technologies Inc.
North America was the largest region in the CD40 ligand (CD40L) antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in CD40 ligand (CD40L) antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the CD40 ligand (CD40L) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The CD40 ligand (CD40L) antibody market consists of revenues earned by entities by providing services such as custom antibody development, recombinant antibody engineering, antibody purification, and functional assays and validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD40 ligand (CD40L) antibody market includes sales of infusion pumps and monoclonal antibody testing systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
CD40 Ligand (CD40L) Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cd40 ligand (cd40l) antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cd40 ligand (cd40l) antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cd40 ligand (cd40l) antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Monoclonal Antibody; Polyclonal Antibody
2) By Application: Flow Cytometry; Enzyme-Linked Immunosorbent Assay (ELISA); Western Blot; Immunoprecipitation; Immunofluorescence; Other Applications
3) By End-User: Hospitals; Research Institutes; Specialty Clinics; Other End-Users
Subsegments:
1) By Monoclonal Antibody: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies
3. CD40 Ligand (CD40L) Antibody Market Trends And Strategies
4. CD40 Ligand (CD40L) Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global CD40 Ligand (CD40L) Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global CD40 Ligand (CD40L) Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global CD40 Ligand (CD40L) Antibody Market Growth Rate Analysis
5.4. Global CD40 Ligand (CD40L) Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global CD40 Ligand (CD40L) Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global CD40 Ligand (CD40L) Antibody Total Addressable Market (TAM)
